14. Pharmacogenomics and nutrigenomics (wk11) Flashcards
2 main goals of pharmacogenomics
1) Search for new drugs and drug targets
2) Influence of genetic variations on drug response in patients
Protein coding genes vs drug targets
400 drug targets
20 000 protein coding genes (and RNA etc)
At least 10x more drug targets than today
Drug response pharmacogenomics
1) Some drugs against diseases are ineffective in certain people
- 30%: beta-blockers in HT, 50 % antidepressants
- Normal- vs altered- vs no response
2) Adverse drug response
- Normal- vs cationary- vs toxic response
* Cause 60-80 % genetic differences between individuals
Pharmacodynamics
What the drug does to the body
Pharmacokinetics
What the body does to the drug ADME: - A: absorption - D: distribution - M: metabolism - E: elimination
Pharmacogenomics
How genetic variations in the pharmacokinetic and pharmacodynamic processes influence the effect and side effect of the drugs
Idiosyncratic
Genetic variations in genes coding for proteins which are not drug target or pharmacokinetic pathways - but could cause side effects
- Ex: urticaria, anaphylaxis etc
- Ex: In favism (G6PD): antimalarial drugs++=> hemolysis
Difficulties of pharmacogenomic researches
1) Phenocopy
2) Gene-gene interactions
3) Ethnic differences
Phenocopy in pharmacogenomics
Environmental factors can cause similar effects as the genetic variants
- Problem in pharmacogenomics
SNP map prediction of medicine response
1) Location of SNP on human DNA
2) Look at SNP genotype of patients with effective clinical trial vs those without - find diff. SNP
3) Isolate these SNP’s and perform clinical trial - predicting efficacy in one nucleotide variant, and no efficacy in the other
* Se bilde ipad
FDA
Food and Drug Administration
- Agency in USA
- Most connected to oncology, then psychiatry
- Ca. 50 % of genes belong to CYP family
Suxamethonium chloride/suxamethonium/succinylcholine
Nicotinic acetylcholine receptor agonist (!)
- Induce muscle relaxation - used in mild anesthesia
- Ex: during intubation
- Butyrylcholinesterase hydrolyses it
Mercaptopurine
Immunosuppressive drug
- Used to treat e.g leukemia
- TPMT: thiopurine methyltransferase metabolizes it
- 3 known variants cause enzyme deficiency
- Dangerous myelosuppression
CYP (cytochrome P-450) gene family
- 57 members
- In liver
- Oxidize endogenous compounds and xenobiotics
- Variants in this gene are responsible for 80 % (!) of all adverse drug responses
- Most important: CYP2D6 & CYP2C19 (& CYP2C8/9)
CYP2D6 metabolism in the population
- 35 %: carriers of non-functional 2D6 allele
- 10 %: slow acting form
- 7 %: super-fast acting form